Dendritic cell-targeting lentiviral vector ID-LV305.

Drug Overview

The medical agent known as LV305 is a cutting-edge type of Immunotherapy used in cancer treatment. It is not a pill or a standard chemotherapy. Instead, it is a biological tool that uses a modified, safe virus to teach the body’s immune system how to recognize and kill cancer cells. This is often referred to as a “cancer vaccine” or a Smart Drug because it targets specific markers found only on certain tumors.

Here are the key details about this agent:

• Generic Name: Dendritic cell-targeting lentiviral vector ID-LV305.
• US Brand Names: None yet. It is currently an investigational drug.
• Drug Class: Immunotherapy / Cancer Vaccine / Lentiviral Vector.
• Route of Administration: Intradermal (injection into the skin).
• FDA Approval Status: Investigational (Currently in advanced clinical trials; not yet approved for general public use).

What Is It and How Does It Work? (Mechanism of Action)

To understand LV305, it helps to think of the immune system as a specialized police force. Sometimes, cancer cells “hide” from this force. LV305 acts like a “Most Wanted” poster, showing the immune system exactly what the cancer looks like so it can be attacked.

The Targeted Virus (Lentiviral Vector)

LV305 uses a “lentiviral vector.” This is a virus that has been hollowed out and made harmless. It cannot cause disease. Instead, it is used as a delivery truck to carry genetic instructions directly into specific immune cells called Dendritic Cells.

Molecular Targeting: The NY-ESO-1 Antigen

Most cancers that LV305 treats produce a specific protein called NY-ESO-1. This protein is usually not found in healthy adult tissues, making it a perfect target. Here is the process at the molecular level:

1. Direct Entry: When LV305 is injected, it seeks out Dendritic Cells in the skin. These cells are the “scouts” of the immune system.
2. Instruction Delivery: The vector enters the Dendritic Cell and delivers the genetic code for the NY-ESO-1 protein.
3. Protein Production: The Dendritic Cell follows these instructions and starts making small pieces of the NY-ESO-1 protein.
4. The Alarm System: The Dendritic Cell then displays these protein pieces on its surface. This “alerts” the rest of the immune system.
5. T-Cell Activation: Specifically, it activates CD8+ T-cells (killer cells). These T-cells travel through the body, find any cell displaying the NY-ESO-1 marker, and destroy it.

FDA-Approved Clinical Indications

Because LV305 is an investigational agent, it does not have official FDA-approved uses for standard care. It is currently being studied in clinical trials for:

Oncological Uses (In Clinical Trials):

• Soft Tissue Sarcoma: Specifically Synovial Sarcoma and Myxoid Round Cell Liposarcoma.
• Melanoma: Advanced skin cancers that have the NY-ESO-1 marker.
• Ovarian Cancer: Recurrent cases where the tumor expresses the specific target protein.
• Non-Small Cell Lung Cancer: Used as part of a combination therapy.

Non-oncological Uses:

• There are currently no non-cancer uses for this drug.

Dosage and Administration Protocols

LV305 is given as a series of small injections into the skin (intradermal). This is usually done in a doctor’s office or a clinical trial center.

Clinical Efficacy and Research Results

Recent research (2020–2025) has focused on how well LV305 works when combined with other immunotherapies.

• Immune Response: In early-phase trials, over 50% of patients showed a significant increase in T-cells specifically designed to fight NY-ESO-1 cancer cells.
• Disease Control: In studies of Sarcoma patients, LV305 has shown the ability to stabilize the disease (stop it from growing) for several months.
• Combination Success: When used with a second agent called G305, the combination (known as CMB305) led to a median overall survival of roughly 18 to 24 months in patients with advanced soft tissue sarcoma, which is a significant improvement for this difficult-to-treat cancer.

Safety Profile and Side Effects

Because LV305 is an immunotherapy and not chemotherapy, it does not usually cause hair loss or severe vomiting. Most side effects are related to the immune system “waking up.”

Common Side Effects (>10%)

• Injection Site Reaction: Redness, itching, or a small bump where the needle went in.
• Flu-like Symptoms: Mild fever, chills, and muscle aches (signs the immune system is working).
• Fatigue: Feeling more tired than usual.

Serious Adverse Events

• Severe Allergic Reaction (Rare): As with any biological product, a very small number of people may have an allergic reaction.
• Autoimmune Response: In rare cases, the immune system may get too excited and attack healthy tissue, though this is uncommon with LV305 compared to other immunotherapies.

Black Box Warning: There is no FDA Black Box Warning for this investigational agent.

Management Strategies

• Fever/Aches: Can usually be managed with over-the-counter pain relievers like acetaminophen.
• Skin Irritation: Avoid scratching the injection site; a cool compress may help.

Research Areas

LV305 is a major part of Regenerative Medicine and Cell Therapy research. Scientists are currently testing how LV305 can be used alongside Stem Cell Transplants. By giving LV305 after a transplant, doctors hope to “train” the new immune system to prevent the cancer from ever coming back. It is also being studied in combination with “Checkpoint Inhibitors” to see if it can make those drugs work in more patients.

Patient Management and Practical Recommendations

Pre-treatment Tests to be Performed

• NY-ESO-1 Testing: A biopsy of the tumor must be tested to confirm the NY-ESO-1 protein is present. If it isn’t, the drug will not work.
• Blood Counts: Standard tests to ensure your immune system is strong enough to respond to the vaccine.

Precautions During Treatment

• You do not need to be isolated. Since the virus in LV305 is modified and cannot spread, you are not “contagious.”
• Monitor your temperature for 48 hours after each injection.

“Do’s and Don’ts” List

• DO stay hydrated before and after your appointment.
• DO tell your doctor if you have any history of autoimmune diseases.
• DON’T apply creams or lotions to the injection site for 24 hours.
• DON’T skip follow-up blood tests, as these measure if your T-cells are increasing.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice. LV305 is an investigational agent and is not currently approved by the US Food and Drug Administration (FDA) for general clinical use. It is available only through participation in approved clinical trials. Always consult with a qualified healthcare professional or your treating oncologist regarding diagnosis, treatment options, and eligibility for clinical trials.